Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164https://doi.org/10.3322/caac.21601
- Colorectal cancer.Lancet. 2019; 394: 1467-1480https://doi.org/10.1016/S0140-6736(19)32319-0
- Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.JAMA Surg. 2015; 150: 402-409https://doi.org/10.1001/jamasurg.2014.3572
- Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.Br J Surg. 2003; 90: 205-214https://doi.org/10.1002/bjs.4015
- Global patterns and trends in colorectal cancer incidence in young adults.Gut. 2019; 68: 2179-2185https://doi.org/10.1136/gutjnl-2019-319511
- Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.J Clin Oncol. 2014; 32: 2975-2984https://doi.org/10.1200/JCO.2013.54.9329
- Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis.Dig Surg. 2016; 33: 157-163https://doi.org/10.1159/000443644
- Two colons-two cancers: paradigm shift and clinical implications.J Surg Oncol. 2004; 88: 261-266https://doi.org/10.1002/jso.20156
- The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis.J Gastrointest Surg. 2016; 20: 648-655https://doi.org/10.1007/s11605-015-3026-6
- Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.Eur J Cancer. 2015; 51: 1405-1414https://doi.org/10.1016/j.ejca.2015.03.015
- Colorectal cancer liver metastases - a population-based study on incidence, management and survival.BMC Cancer. 2018; 18: 78https://doi.org/10.1186/s12885-017-3925-x
- Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2017; 3: 211-219https://doi.org/10.1001/jamaoncol.2016.4227
- Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study.BJS Open. 2020; 4: 685-692https://doi.org/10.1002/bjs5.50299
- Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases.Br J Surg. 2015; 102: 691-699https://doi.org/10.1002/bjs.9783
- The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment.Ann Surg. 1984; 199: 502-508https://doi.org/10.1097/00000658-198405000-00002
- Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Assoc Francaise de Chirurgie.Cancer. 1996; 77: 1254-1262
- Guidelines for resection of colorectal cancer liver metastases.Gut. 2006; 55: 1-8https://doi.org/10.1136/gut.2006.098053
- Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging.Eur J Radiol. 2011; 77: 468-472https://doi.org/10.1016/j.ejrad.2009.09.002
- Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma.Ann Surg. 2014; 259: 861-872https://doi.org/10.1097/SLA.0000000000000525
- Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI.J Magn Reson Imaging. 2011; 34: 326-335https://doi.org/10.1002/jmri.22613
- Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study.BMC Cancer. 2021; 21: 1116https://doi.org/10.1186/s12885-021-08833-1
- Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?.Surgery. 2018; 163: 1238-1244https://doi.org/10.1016/j.surg.2018.01.004
- Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Ann Surg. 1999; 230 (; discussion 318-21): 309-318https://doi.org/10.1097/00000658-199909000-00004
- The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases.Arch Surg. 2004; 139: 1168-1172https://doi.org/10.1001/archsurg.139.11.1168
- Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors.World J Gastroenterol. 2006; 12: 6305-6309https://doi.org/10.3748/wjg.v12.i39.6305
- Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases.Liver Int. 2009; 29: 89-102https://doi.org/10.1111/j.1478-3231.2008.01845.x
- Correction to: Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon.Ann Surg Oncol. 2021; 28: 879https://doi.org/10.1245/s10434-021-10185-w
- Real-time intraoperative assessment of residual liver functional reserve using pulse dye densitometry.World J Surg. 2008; 32: 2668-2674https://doi.org/10.1007/s00268-008-9752-0
- Post-hepatectomy liver failure.Hepatobiliary Surg Nutr. 2014; 3: 238-246https://doi.org/10.3978/j.issn.2304-3881.2014.09.01
- Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis.Ann Surg. 2018; 267: 1047-1055https://doi.org/10.1097/SLA.0000000000002552
- Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.Ann Surg. 2005; 241 (discussion 722-4): 715-722https://doi.org/10.1097/01.sla.0000160703.75808.7d
- Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.Ann Surg. 2017; 266: 641-649https://doi.org/10.1097/SLA.0000000000002367
- Resection margin and recurrence-free survival after liver resection of colorectal metastases.Ann Surg Oncol. 2010; 17: 1324-1329https://doi.org/10.1245/s10434-009-0770-4
- Parenchymal-Sparing Hepatectomy Does Not Increase Intrahepatic Recurrence in Patients with Advanced Colorectal Liver Metastases.Ann Surg Oncol. 2016; 23: 3718-3726https://doi.org/10.1245/s10434-016-5278-0
- Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4,152 resections for malignancy.J Am Coll Surg. 2015; 220: 471-479https://doi.org/10.1016/j.jamcollsurg.2014.12.026
- Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: A systematic review and meta-analysis.Cancer Med. 2019; 8: 6165-6175https://doi.org/10.1002/cam4.2515
- Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review.J Gastrointest Surg. 2017; 21: 1076-1085https://doi.org/10.1007/s11605-017-3397-y
- Parenchymal-sparing hepatectomy for deep-placed colorectal liver metastases.Surgery. 2016; 160: 1256-1263https://doi.org/10.1016/j.surg.2016.06.041
- Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival.Ann Surg. 2016; 263: 146-152https://doi.org/10.1097/SLA.0000000000001194
- Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).Ann Oncol. 2012; 23: 2619-2626https://doi.org/10.1093/annonc/mds053
- Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.Ann Surg. 2007; 246 (; discussion 565-7): 559-565https://doi.org/10.1097/SLA.0b013e318155a7b6
- Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma.Cancer. 2000; 89: 276-284
- Laparoscopic versus open liver resection for colorectal liver metastases: a systematic review.J Surg Res. 2017; 220: 234-246https://doi.org/10.1016/j.jss.2017.05.110
- Survival Advantage of Laparoscopic Versus Open Resection For Colorectal Liver Metastases: A Meta-analysis of Individual Patient Data From Randomized Trials and Propensity-score Matched Studies.Ann Surg. 2020; 272: 253-265https://doi.org/10.1097/SLA.0000000000003672
- Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial.Ann Surg. 2018; 267: 199-207https://doi.org/10.1097/SLA.0000000000002353
- Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.J Clin Oncol. 2006; 24: 4976-4982https://doi.org/10.1200/JCO.2006.06.8353
- Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.J Clin Oncol. 2008; 26: 4906-4911https://doi.org/10.1200/JCO.2008.17.3781
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).Ann Oncol. 2009; 20: 674-680https://doi.org/10.1093/annonc/mdn680
- Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial.J Clin Oncol. 2021; 39: 3789-3799https://doi.org/10.1200/JCO.21.01032
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.Lancet. 2008; 371: 1007-1016https://doi.org/10.1016/S0140-6736(08)60455-9
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2013; 14: 1208-1215https://doi.org/10.1016/S1470-2045(13)70447-9
- Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.BMC Cancer. 2015; 15: 180https://doi.org/10.1186/s12885-015-1199-8
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.Lancet Oncol. 2014; 15: 601-611https://doi.org/10.1016/S1470-2045(14)70105-6
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.Lancet Oncol. 2020; 21: 398-411https://doi.org/10.1016/S1470-2045(19)30798-3
- The blood supply of neoplasms in the liver.Am J Pathol. 1954; 30: 969-977
- Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver.Cancer. 1962; 15: 472-488
- Chemotherapy of Metastatic Liver Cancer by Prolonged Hepatic-Artery Infusion.N Engl J Med. 1964; 270: 321-327https://doi.org/10.1056/NEJM196402132700701
- Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.N Engl J Med. 1999; 341: 2039-2048https://doi.org/10.1056/NEJM199912303412702
- Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.J Surg Oncol. 2016; 113: 477-484https://doi.org/10.1002/jso.24189
- Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.J Clin Oncol. 2017; 35: 1938-1944https://doi.org/10.1200/JCO.2016.71.8346
- Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.Ann Surg. 2020; 272: 352-356https://doi.org/10.1097/SLA.0000000000003248
- A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma.Surg Oncol Clin N Am. 2003; 12 (xi): 165-192https://doi.org/10.1016/s1055-3207(02)00091-1
- Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann Surg. 2004; 240 ([discussion: 657-8]): 644-657https://doi.org/10.1097/01.sla.0000141198.92114.f6
- Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Ann Oncol. 2004; 15: 933-939https://doi.org/10.1093/annonc/mdh217
- Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg. 1996; 224 ([discussion 520-2]): 509-520https://doi.org/10.1097/00000658-199610000-00009
- A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.Ann Surg Oncol. 2013; 20: 4289-4297https://doi.org/10.1245/s10434-013-3217-x
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.Lancet Oncol. 2010; 11: 38-47https://doi.org/10.1016/S1470-2045(09)70330-4
- Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).Ann Oncol. 2014; 25: 1018-1025https://doi.org/10.1093/annonc/mdu088
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med. 2009; 360: 1408-1417https://doi.org/10.1056/NEJMoa0805019
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.Ann Oncol. 2011; 22: 1535-1546https://doi.org/10.1093/annonc/mdq632
- Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol. 2009; 27: 663-671https://doi.org/10.1200/JCO.2008.20.8397
- Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.Ann Oncol. 2015; 26: 702-708https://doi.org/10.1093/annonc/mdu580
- Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.J Clin Oncol. 2020; 38: 3175-3184https://doi.org/10.1200/JCO.20.00174
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.Lancet Oncol. 2014; 15: 1065-1075https://doi.org/10.1016/S1470-2045(14)70330-4
- FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.Br J Cancer. 2021; 124: 587-594https://doi.org/10.1038/s41416-020-01140-9
- Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).Br J Cancer. 2019; 121: 222-229https://doi.org/10.1038/s41416-019-0518-2
- The 'small for size' liver syndrome.Curr Opin Crit Care. 2005; 11: 150-155https://doi.org/10.1097/01.ccx.0000157080.11117.45
- Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors.Ann Surg. 2000; 232: 777-785https://doi.org/10.1097/00000658-200012000-00006
- A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.Ann Surg. 2004; 240 ([discussion: 1049-51]): 1037-1049https://doi.org/10.1097/01.sla.0000145965.86383.89
- Relation of the Portal Blood to Liver Maintenance : A Demonstration of Liver Atrophy Conditional on Compensation.J Exp Med. 1920; 31: 609-632https://doi.org/10.1084/jem.31.5.609
- James Cantlie's early messages for hepatic surgeons: how the concept of pre-operative portal vein occlusion was defined.HPB (Oxford). 2010; 12: 81-83
- Preoperative portal vein embolization for hepatocellular carcinoma.World J Surg. 1986; 10: 803-808https://doi.org/10.1007/BF01655244
- Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.Surgery. 1990; 107: 521-527
- Ligation of a branch of the portal vein for carcinoma of the liver.Am J Surg. 1975; 130: 296-302https://doi.org/10.1016/0002-9610(75)90389-x
- Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant.J Am Coll Surg. 2013; 216: 201-209https://doi.org/10.1016/j.jamcollsurg.2012.10.018
- Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.J Am Coll Surg. 2014; 219: 620-630https://doi.org/10.1016/j.jamcollsurg.2014.04.022
- High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.J Clin Oncol. 2011; 29: 1083-1090https://doi.org/10.1200/JCO.2010.32.6132
- Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy.Ann Surg. 2009; 249: 608-616https://doi.org/10.1097/SLA.0b013e31819ecc5c
- Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.Ann Surg. 2012; 255: 405-414https://doi.org/10.1097/SLA.0b013e31824856f5
- Hypertrophy and Liver Function in ALPPS: Correlation with Morbidity and Mortality.Visc Med. 2017; 33: 426-433https://doi.org/10.1159/000479477
- ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial).Ann Surg. 2018; 267: 833-840https://doi.org/10.1097/SLA.0000000000002511
- ALPPS Improves Survival Compared With TSH in Patients Affected of CRLM: Survival Analysis From the Randomized Controlled Trial LIGRO.Ann Surg. 2021; 273: 442-448https://doi.org/10.1097/SLA.0000000000003701
- Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy.Br J Surg. 2016; 103: 1768-1782https://doi.org/10.1002/bjs.10290
- FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol. 2004; 22: 229-237https://doi.org/10.1200/JCO.2004.05.113
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.Lancet Oncol. 2013; 14: 29-37https://doi.org/10.1016/S1470-2045(12)70477-1
- Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.J Clin Oncol. 2021; 39: 3693-3704https://doi.org/10.1200/JCO.21.01436
- Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).J Clin Oncol. 2006; 24: 1395-1403https://doi.org/10.1200/JCO.2005.03.8166
- Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.Ann Surg. 2015; 261: 353-360https://doi.org/10.1097/SLA.0000000000000614
- Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.J Surg Oncol. 2018; 117: 634-643https://doi.org/10.1002/jso.24898
- Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases.J Am Coll Surg. 2005; 201: 57-65https://doi.org/10.1016/j.jamcollsurg.2005.03.019
- Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases.J Surg Oncol. 2018; 118: 1065-1073https://doi.org/10.1002/jso.25249
- Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.Ann Surg Oncol. 2020; https://doi.org/10.1245/s10434-020-08972-y
- Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.Ann Surg Oncol. 2017; 24: 150-158https://doi.org/10.1245/s10434-016-5418-6
- Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study.J Surg Oncol. 2021; 123: 252-260https://doi.org/10.1002/jso.26270
- Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases.Ann Surg. 2020; 271: 212-218https://doi.org/10.1097/SLA.0000000000003404
- Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases.JAMA Surg. 2021; 156: 550-557https://doi.org/10.1001/jamasurg.2021.0267
- Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.JAMA Surg. 2022; https://doi.org/10.1001/jamasurg.2022.0300
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).J Clin Oncol. 2020; 38: 2053-2061https://doi.org/10.1200/JCO.19.03296
- Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA Netw Open. 2022; 5: e2149040https://doi.org/10.1001/jamanetworkopen.2021.49040
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.Nat Med. 2021; 27: 152-164https://doi.org/10.1038/s41591-020-1131-x
Article info
Publication history
Published online: November 03, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
